7G. I. Owen,A. Zelent*. Origins and evolutionary diversification of the nuclear receptor superfamily[J] 2000,Cellular and Molecular Life Sciences(5):809～827
二级参考文献93
1[12]Ciaraldi TP, Gilmore A, Olefsky JM et al. In vitro studies on the action s of CS-045. A new antidiabetic agent. Metabolism, 1990;39(10):1056～62
2[13]Burant2 CF, Screenan S, Hirano K et al. Troglitazone action is independent of adipose tissue. J Clin Invest, 1997;100(11):2900～8
3[14]Lee MK, Olefsky JM. Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism, 1995;44(9):1166～9
4[15]Preininger K, Stingl P, Englisch R et al. Acute troglitazone action in isolated perfused rat liver. Br J Pharmacol, 1999;126(1):372～8
5[16]Henry RR. Thiazolidinedione. Endocrinol Metab Clin North Am, 1997;26(3):9553～73
6[17]Gimble JM, Robinson CE, Wu X et al. Peroxisome proliferatior-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol, 1996;50(5):1087～94
7[18]Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther, 2000;22(10):1151～68
8[19]Forman, BM, Tontonoz P, Chen J et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell, 1995;83(5): 813～9
9[20]Houseknecht KL, Vanden, Heuvel JP et al. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. Biochem Biophys Res Commun, 1998;244(3):678～82
10[21]Ryder JW, Portocarrero CP, Song XM et al. I somer-specific antidiabetic properties of conjugated linoleic acid. Improved glucose tolerance,skeletal muscle insulin action, and UCP-2 gene expression. Diabetes, 2001;50(5):1149～57
2Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review [J]. Curr Opin Pediatr, 2005,17(5): 636-641.
3Adams LA, Waters OR, Knuiman MW, et at. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study [J]. Am J Gastroenterol, 2009 ,104(4): 861-867.
4Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study[J]. Hepatology, 2005, 42:44-52.
5Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis[J].Hepatology,2006,43:S99-112.
6Fan JG, Zhu J, Li XI, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China [J]. J Hepatol, 2005,43: 508- 514.
7Day CP, James OF. Hepatic steatosis: Irmcent bystander or guilty party? [J]. Hepatology,1998,27:1463-1466.
8Ren D, Collingwood TN, Rebar EJ, et al. PPARy knockdown by engineered transcription factors :exogenous PPARy 2 but not PPARy 1 reactivates adipogenesis[J]. Genes Dev, 2002,16:27-32.
